WO2010068810A3 - Certain substituted amides, method of making, and method of use thereof - Google Patents
Certain substituted amides, method of making, and method of use thereof Download PDFInfo
- Publication number
- WO2010068810A3 WO2010068810A3 PCT/US2009/067575 US2009067575W WO2010068810A3 WO 2010068810 A3 WO2010068810 A3 WO 2010068810A3 US 2009067575 W US2009067575 W US 2009067575W WO 2010068810 A3 WO2010068810 A3 WO 2010068810A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- making
- btk
- substituted amides
- certain substituted
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
Compounds of Formula (I) that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula (I), together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and / or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12140308P | 2008-12-10 | 2008-12-10 | |
US61/121,403 | 2008-12-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010068810A2 WO2010068810A2 (en) | 2010-06-17 |
WO2010068810A3 true WO2010068810A3 (en) | 2011-02-10 |
Family
ID=41559565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/067575 WO2010068810A2 (en) | 2008-12-10 | 2009-12-10 | Certain substituted amides, method of making, and method of use thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010068810A2 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2552514T3 (en) * | 2011-11-03 | 2015-11-30 | Hoffmann-La Roche Ag | Bicyclic Piperazine Compounds |
US9365566B2 (en) | 2012-03-27 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives |
JP6182593B2 (en) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | Substituted heterobicyclic compounds, compositions and medicaments and uses thereof |
WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
TW201414737A (en) * | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | Imidazotriazinecarbonitriles useful as kinase inhibitors |
JP6575950B2 (en) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Mutations with resistance to Bruton tyrosine kinase (Btk) inhibitors |
JO3377B1 (en) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | Pyridinyl and fused pyridinyl triazolone derivatives |
ES2619125T3 (en) | 2013-04-25 | 2017-06-23 | Beigene, Ltd. | Heterocyclic compounds fused as protein kinase inhibitors |
JP6623353B2 (en) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | Anti-PD-1 antibodies and their use for therapy and diagnosis |
WO2015157955A1 (en) | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
JP6526189B2 (en) | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | Anti-PD-L1 antibodies and their use for therapy and diagnosis |
EP3042903B1 (en) | 2015-01-06 | 2019-08-14 | Impetis Biosciences Ltd. | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
WO2016165831A1 (en) | 2015-04-17 | 2016-10-20 | Curevac Ag | Lyophilization of rna |
EP3297682B1 (en) | 2015-05-20 | 2021-07-14 | CureVac AG | Dry powder composition comprising long-chain rna |
WO2016184575A1 (en) | 2015-05-20 | 2016-11-24 | Curevac Ag | Dry powder composition comprising long-chain rna |
AU2017240609B2 (en) | 2016-03-31 | 2021-07-15 | Takeda Pharmaceutical Company Limited | Isoquinolinyl triazolone complexes |
CN109475536B (en) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | Combination of a PD-l antagonist and a RAF inhibitor for the treatment of cancer |
CN109563099B (en) | 2016-08-16 | 2023-02-03 | 百济神州有限公司 | Crystal form of compound, preparation and application thereof |
AU2017313085A1 (en) | 2016-08-19 | 2019-03-14 | Beigene Switzerland Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
JP2019529419A (en) | 2016-09-19 | 2019-10-17 | エムイーアイ ファーマ,インク. | Combination therapy |
CN110461847B (en) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | Crystalline forms of (S) -7- (1- (but-2-alkynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4,5,6, 7-tetrahydropyrazolo [1,5-a ] pyrimidine-3-carboxamide, preparation and use thereof |
CA3066518A1 (en) | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
CN110997677A (en) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | Btk inhibitors with improved dual selectivity |
WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
CN111825675B (en) * | 2019-04-15 | 2023-08-01 | 武汉朗来科技发展有限公司 | ROCK inhibitor and preparation method and application thereof |
WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007038314A2 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
WO2008116064A2 (en) * | 2007-03-21 | 2008-09-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0608252A2 (en) | 2005-03-10 | 2010-04-06 | Cgi Pharmaceuticals Inc | chemical entities, pharmaceutical compositions comprising them, methods using said chemical entities and use of said chemical entities |
-
2009
- 2009-12-10 WO PCT/US2009/067575 patent/WO2010068810A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007038314A2 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
WO2008116064A2 (en) * | 2007-03-21 | 2008-09-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
Non-Patent Citations (1)
Title |
---|
FAUCI, A.S.; BRAUNWALD, E.; ISSELBACHER, K.J.; WILSON, J.D.; MARTIN, J.>B.; KASPER, D.L.; HAUSER, S.L.; LONGO, D.L.: "Harrison's Principles of Internal Medicine", 1998, MCGRAW-HILL, ISBN: 0070202915, XP002566174, 1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010068810A2 (en) | 2010-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010068810A3 (en) | Certain substituted amides, method of making, and method of use thereof | |
WO2009039397A3 (en) | Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer | |
WO2008033857A3 (en) | Substituted amides, method of making, and method of use thereof | |
GEP20125624B (en) | Pyridazine derivatives as smo inhibitors | |
WO2006059245A3 (en) | Compounds for the treatment of cns and amyloid associated diseases | |
MX2009002649A (en) | Certain substituted amides, method of making, and method of use thereof. | |
WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same | |
WO2006099075A3 (en) | Certain substituted amides, method of making, and method of use thereof | |
WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
WO2007143600A3 (en) | Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases | |
WO2009066152A3 (en) | Haloallylamine inhibitors of ssao/vap-1 and uses therefor | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
MX2011011854A (en) | Dihydropyrimidinones for use as bace2 inhibitors. | |
WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
WO2005075425A3 (en) | Substituted bisarylurea derivatives as kinase inhibitors | |
TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
WO2006081431A3 (en) | Compounds for treating inflammatory and demyelinating diseases | |
IN2015DN04175A (en) | ||
WO2005077462A3 (en) | Cd70 inhibition for the treatment and prevention of inflammatory bowel disease | |
IL193252A0 (en) | N-hydroxyacrylamide compounds | |
WO2009030952A3 (en) | Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway | |
EA200201276A1 (en) | ARYLMETYLAMINE DERIVATIVES FOR USE AS TRIPTASE INHIBITORS | |
NZ592927A (en) | PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY | |
WO2009041787A3 (en) | Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease | |
WO2011159124A3 (en) | Novel benzoxazole derivative having inhibitory activity against interleukin-6, preparation method thereof, and pharmaceutical composition containing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09768590 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09768590 Country of ref document: EP Kind code of ref document: A2 |